Skip to content
OpenCapital
Get started

Praxis Precision Medicines, Inc. PRAX Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax

Other financials

Income statement

See full
Revenue--100%
Operating income-$105.9M-41.7%
Net income-$92.6M-33.6%
EPS (diluted)-$3.20+2.7%

Balance sheet

See full
Cash & equivalents$536.7M+223%
Total debt$1.4M+31.3%
Total equity$1.4B+221%
Total assets$1.5B+205%

Cash flow

See full
Operating cash flow-$86.2M-62.5%
CapEx$62.0K—
Free cash flow-$86.2M-62.6%

Valuation

See full
Market cap$7.87B+1,075%
Enterprise value$7.34B+1,309%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-35.3%-10.9pp
Debt / equity0×0.0×
Current ratio15.9×+7.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept prax:CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Praxis Precision Medicines, Inc.'s cash equivalents and debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Praxis Precision Medicines, Inc.'s cash equivalents and debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Praxis Precision Medicines, Inc. (PRAX) reported cash equivalents and debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $1.59M in Q1 2026.